Senseonics Holdings, Inc. SENS | NASDAQ
|2026-09-09
Company Overview:
10 Year SENS Performance Metrics:
Build Custom Charts
SENS Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for SENS
Based on past 10-year performance, here are SENS growth metrics:
Share price CAGR of -13.24%
Dividend CAGR of +0%
Using SENS CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| SENS (DRIP) | SENS - No DRIP | |
|---|---|---|
| Current Price | $10.58 | $10.58 |
| Start Shares | 945.18 | 945.18 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 945.18 | 945.18 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $2.56 | $10.58 |
| Total Dividends | $0 | $0 |
| Final Value | $2,416 | $10,000 |
NOTE: Above numbers are our estimate based on SENS's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Senseonics Holdings, Inc. (SENS) had its IPO on 2015-12-22, and is traded on NASDAQ stock exchange.
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
SENS website: https://www.senseonics.com
DCF Model — SENS
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
